Biotage AB (publ)
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation produ… Read more
Biotage AB (publ) (BITGF) - Total Assets
Latest total assets as of March 2025: $4.71 Billion USD
Based on the latest financial reports, Biotage AB (publ) (BITGF) holds total assets worth $4.71 Billion USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biotage AB (publ) - Total Assets Trend (2014–2024)
This chart illustrates how Biotage AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biotage AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Biotage AB (publ)'s total assets of $4.71 Billion consist of 26.6% current assets and 73.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.5% |
| Accounts Receivable | $357.00 Million | 7.0% |
| Inventory | $458.00 Million | 9.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $765.00 Million | 15.0% |
| Goodwill | $2.56 Billion | 50.2% |
Asset Composition Trend (2014–2024)
This chart illustrates how Biotage AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biotage AB (publ)'s current assets represent 26.6% of total assets in 2024, a decrease from 49.8% in 2014.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2024, down from 15.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 64.0% of total assets, an increase from 21.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 50.2% of total assets.
Biotage AB (publ) Competitors by Total Assets
Key competitors of Biotage AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Biotage AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Biotage AB (publ) generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Biotage AB (publ) generates $5.56 in net profit.
Biotage AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.53 | 2.16 | 3.27 |
| Quick Ratio | 1.61 | 1.52 | 2.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $729.00 Million | $ 799.00 Million | $ 454.71 Million |
Biotage AB (publ) - Advanced Valuation Insights
This section examines the relationship between Biotage AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.04 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | $5.10 Billion |
| Market Capitalization | $709.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biotage AB (publ)'s assets below their book value (0.14 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Biotage AB (publ)'s assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biotage AB (publ) (2014–2024)
The table below shows the annual total assets of Biotage AB (publ) from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.10 Billion | +3.51% |
| 2023-12-31 | $4.93 Billion | +110.82% |
| 2022-12-31 | $2.34 Billion | +17.42% |
| 2021-12-31 | $1.99 Billion | +38.87% |
| 2020-12-31 | $1.43 Billion | +7.39% |
| 2019-12-31 | $1.34 Billion | +33.14% |
| 2018-12-31 | $1.00 Billion | +32.49% |
| 2017-12-31 | $757.20 Million | +8.92% |
| 2016-12-31 | $695.20 Million | +3.94% |
| 2015-12-31 | $668.83 Million | +5.74% |
| 2014-12-31 | $632.51 Million | -- |